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Huntington's diseaseMitochondrial Ca2+ accumulation is a tightly controlled process, in turn regulating functions as diverse as
aerobic metabolism and induction of cell death. The link between Ca2+ (dys)regulation, mitochondria and
cellular derangement is particularly evident in neurodegenerative disorders, in which genetic models and
environmental factors allowed to identify common traits in the pathogenic routes. Wewill here summarize: i)
the current view of mechanisms and functions of mitochondrial Ca2+ homeostasis, ii) the basic principles of
organelle Ca2+ transport, iii) the role of Ca2+ in neuronal cell death, and iv) the new information on the
pathogenesis of Alzheimer's, Huntington's and Parkinson's diseases, highlighting the role of Ca2+ and
mitochondria.
© 2009 Elsevier B.V. All rights reserved.1. Mitochondria in calcium signalling
The notion that mitochondria are active players in cellular calcium
homeostasis dates back to the demonstration of the chemiosmotic
theory, based on the concept of a major proton electrochemical
gradient that could drive the rapid accumulation of cations across the
ion-impermeant mitochondrial inner membrane. Such a notion was
corroborated by the direct measurement of Ca2+ uptake by isolated
mitochondria, and the functional, albeit not molecular, elucidation of
the transporters [1].
However, the experiments that in the 80s drove massive interest
into calcium as a ubiquitous second messenger also led to the gradual
decline in the attention on mitochondrial Ca2+ homeostasis. On the
one hand, it appeared clear that the endoplasmic reticulum (ER),
through resident Ca2+ channels (those sensitive to inositol 1,4,5
trisphosphate, IP3R, and to the plant alkaloid ryanodine, RyR) acts as
the intracellular pool of Ca2+ mobilized upon cell stimulation. On the
other, the development of accurate ﬂuorescent indicators for the
measurement of Ca2+ concentration in living cells showed that
cytosolic Ca2+ concentration ﬂuctuates between approx. 0.1 μMat rest
to 2–3 μM at the peak of the rise elicited by the opening of plasma+39 0498276049.
.
ll rights reserved.membrane or ER Ca2+ channels. Under those conditions, the low
afﬁnity of the mitochondrial Ca2+ transporters should allow little Ca2+
uptake into the organelle. Thus, the prevalent notion was that
mitochondrial Ca2+ accumulation is negligible in physiological condi-
tions, and could become relevant only uponmassive Ca2+ overload, that
could take place in severe cellular dysfunction.
This situationwas completely reversedwhen tools were developed
that allowed the selective measurement of mitochondrial Ca2+
concentration ([Ca2+]m) in living cells. Targeting to mitochondria
the Ca2+-sensitive photoprotein aequorin [2] demonstrated that a
rapid [Ca2+]m peak, reaching values well above those of the bulk
cytosol, parallels the [Ca2+] rise evoked in the cytoplasm by cell
stimulation [3]. Similar conclusions could be reached also with
ﬂuorescent indicators, such as the positively charged Ca2+ indicator
rhod 2 (that accumulates within the organelle) [4] and the more
recently developed GFP-based ﬂuorescent indicators [5]. With the
latter probes, endowed with a much stronger signal than the
photoprotein, single-cell imaging of organelle Ca2+ could be carried
out [6]. With these tools in hands, not only the notion was conﬁrmed
that mitochondria promptly respond to cytosolic [Ca2+] rises, but also
that the [Ca2+]c oscillations, the typical response to agonists of many
cell types, are paralleled by rapid spiking of [Ca2+]m, thus providing a
frequency-mediated signal speciﬁcally decoded within the mitochon-
dria, as clearly shown in hepatocytes [7], cardiomyocytes [8], and HeLa
cells [9]. The apparent discrepancy between the promptness and
amplitude of the mitochondrial Ca2+ response and the low afﬁnity of
Fig. 1. Schematic map of mitochondrial Ca2+ transporters. Mitochondria accumulate
Ca2+ in the matrix via an electrogenic Ca2+ uniporter (MCU) that acts to equilibrate Ca2+
according the electrochemical gradient generated by the respiratory chain (ETC). Voltage
Dependent Anion Channel (VDAC) controls the Ca2+ diffusion through the outer
mitochondrial membrane (OMM), thus facilitating mitochondrial Ca2+ accumulation. As
to the efﬂux pathways, a Na+/Ca2+ and a H+/Ca2+ exchangers have been shown to
operate. The permeability transition pore (PTP) opening plays different roles: its brief
opening could allow rapid Ca2+ release, but its long-lasting openings (potentiated by
apoptotic stimuli and Ca2+ itself) could trigger cell death process. IMS, intermembrane
space; IMM, inner mitochondrial membrane.
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mitochondria are in close contact with the source of the cytosolic Ca2+
rise (i.e. the ER via IP3Rs and RyRs and the plasma membrane via a
wide variety of voltage- and agonist-sensitive Ca2+ channels). Thus,
upon cell stimulation they are exposed to microdomains of high [Ca2+]
that greatly exceed the values measured in the cytosol and well match
the afﬁnity of mitochondrial Ca2+ transporters [10].
As soon as the concept was established that a Ca2+ rise in the
cytosol is paralleled by a cycle of mitochondrial Ca2+ uptake, and
subsequent release (through the pathways that will be brieﬂy
described later), the identiﬁcation of the functional signiﬁcance of
this process became a primary goal. Also in this task, the ﬁne
biochemical work carried out in the 70s provided a hypothesis to test:
three key metabolic enzymes (the pyruvate, ketoglutarate and
isocitrate dehydrogenases) were shown to be activated by Ca2+ by
different mechanisms: in the case of pyruvate dehydrogenase through
a Ca2+-dependent dephosphorylation step, in the latter two cases
through the direct binding of Ca2+ to the enzyme complex [11].
Recently, also some metabolite transporters were shown to be
regulated by Ca2+ and participate in the enhancement of aerobic
metabolism upon cell stimulation [12]. Thus, an obvious role for
mitochondrial Ca2+ accumulation could be inferred, i.e. that of rapidly
upregulating mitochondrial ATP production in stimulated cells. The
possibility of directly monitoring, in parallel, Ca2+ and ATP levels
within mitochondria and in the cytosol proved that this is indeed the
case [13]. Interestingly, this route for controlling mitochondrial
metabolic output proved to be affected in mitochondrial genetic
disorders. In cybrids harboring the tRNAlys mutation of MERRF
(myoclonic epilepsy with ragged-red ﬁbers), mitochondrial Ca2+
responses were reduced, and, accordingly, ATP production upon cell
stimulation, and the pharmacological correction of the Ca2+ alteration
also restored the metabolic dysfunction [14,15].
In addition to the functionofmetabolic coupling,mitochondrial Ca2+
accumulation was shown to underlie a role for these organelles in
shaping the spatio/temporal patterning of cytosolic Ca2+ rises.
Mitochondria, distinctly from cytosolic proteins, are highly sophisti-
cated, “tunable” buffers that vary their activity in different phases and
functional states of the cell; indeed, their number, shape, distribution
[16] and most likely their responsiveness to Ca2+ [17] are controlled by
converging signalling pathways. This Ca2+ buffering activity inﬂuences
cytosolic Ca2+ signals in two conceptually different ways, i.e., 1) by
acting as high-capacity sinks placed on the way of a propagating Ca2+
wave and 2) by clearing Ca2+ in restricted microdomains (such as the
microenvironment of a Ca2+ channel). In theﬁrst case, spatial clusters of
mitochondria have been demonstrated to isolate functionally distinct
domains of polarized cells, namely, a mitochondrial “ﬁrewall” was
shown to prevent the spread of Ca2+ signals from the apical (secretory)
region of pancreatic acinar cell from the basolateral region, containing
the nucleus [18]. Similarly, neuronal mitochondria have been shown to
buffer [Ca2+] increases in deﬁned cellular regions, e.g., the presynaptic
motoneuron ending [19]. As to the second case, a thoroughly
investigated example is the regulation of Ca2+ release through IP3Rs.
In Xenopus oocytes, the mitochondria energization state (and thus
the capacity to accumulate Ca2+) was shown tomodify the propagating
Ca2+ waves induced by IP3 [20]. In permeabilized blowﬂy salivary
glands, it was observed that perfusion of IP3 induced ER [Ca2+]
oscillations, the frequency of which increased with the dose of IP3.
Such an effect was observed only upon energization of mitochondria,
implying a primary role of these organelles in regulating Ca2+
microdomains in the proximity of IP3Rs and thus the oscillatory pace
of stimulated cells [21]. In mammals, this effect has been seen in many
cell systems, includinghepatocytes,HeLa cells, astrocytes, and BHKcells.
As to the cellular consequence, very different effects were observed
given the bell-shaped sensitivity of IP3Rs to Ca2+ concentration on the
cytosolic side. In astrocytes and hepatocytes, cytosolic excitability
appeared enhanced when mitochondrial Ca2+ uptake was inhibited,indicating that mitochondrial clearance of the Ca2+ microdomain
reduced the positive Ca2+ feedback on the IP3R and/or buffered
substantial Ca2+ loads [22]. Conversely, in BHK cells, inhibition of
mitochondrial Ca2+uptake resulted in reduction of ERCa2+ release [23],
thus indicating that mitochondria prevent the Ca2+-dependent inacti-
vation of the channel.
The interest in the process of mitochondrial Ca2+ homeostasis
dramatically increased when it became apparent that also cell death is
causally linked to organelle Ca2+ loading. On the one hand, it was
clear that cellular Ca2+ overload, such as that caused by hyperstimu-
lation of ionotropic glutamate receptors, leads to Ca2+ cycling across
the mitochondrial membranes, collapse of the proton gradient and
bioenergetic catastrophe, thus leading to cell death by necrosis, as
discussed in more detail later in this review. On the other hand, Ca2+
proved to sensitize cells to apoptotic challenges, acting on the
mitochondrial checkpoint. This notion, subsequently conﬁrmed by
the study of other anti- and pro-apoptotic proteins, emerged from the
analysis of the effect of Bcl-2 on Ca2+ signalling. We refer to other
speciﬁcally focused reviews for a detailed coverage of this topic [24].
Brieﬂy, we here summarize that Bcl-2, by partially emptying the ER
Ca2+ store, reduces the release from this organelle and the loading of
mitochondria. As a consequence, the efﬁcacy of apoptotic challenges
in opening the permeability transition pore (PTP), causing mitochon-
drial morphological alterations and releasing caspase cofactors, such
as cytochrome c, is greatly reduced [25].
2. The basics of mitochondrial Ca2+ transport
For entering the mitochondrial matrix, Ca2+ needs to cross two
lipid bilayers, the outer and inner mitochondrial membranes (Fig. 1).
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small proteins (MWb10 kDa) due to the abundance of a large
conductance channel, known as mitochondrial porin or voltage-
dependent anion channel (VDAC). It should be noted, however, that
the channel appears to be gated in vivo, and permeability is controlled
by ATP and other regulatory factors [26]. Ca2+ diffusion through the
OMM was thus traditionally considered not to be a limiting factor in
mitochondrial Ca2+ uptake. Recent data showed that the availability
and selective placement of VDAC channels at ER/mitochondria
contact sites facilitate mitochondrial Ca2+ accumulation, in keeping
with the idea that the latter process requires the fast and efﬁcient
transfer of Ca2+ microdomains from the mouth of the Ca2+ channels
located in neighbouring ER or plasma membranes to the transporters
of the ion-impermeant inner membrane (IMM) [27]. The IMM is an
ion-impermeable membrane, with a much larger extension of the
OMM (and consequent formation of foldings into the internal space,
known as cristae). The activity of respiratory chain complexes allows
the translocation of H+ in the space between the two membranes,
which consequently generates an electrochemical gradient (ΔμH)
composed of a chemical (ΔpH) and electrical (ΔψH) component. In
mitochondria, most of the ΔμH established by the respiratory chain is
supposed to be in the form of ΔψH (around −180 mV), which
provides a huge driving force for Ca2+ entry into the organelle. Indeed,
collapse of the ΔψH by protonophores, such as p-[triﬂuoromethoxyl]-
phenyl-hydrazone (FCCP), abolishes mitochondrial Ca2+ uptake.
Mitochondrial Ca2+ trafﬁc takes place essentially through two
pathways: i) an electrogenic pathway, the mitochondrial Ca2+
uniporter (MCU), corresponding to the channel activity demonstrated
by Clapham et al. [28] that acts to equilibrate Ca2+ with its
electrochemical gradient, and thus accumulates the cation into the
matrix; ii) two exchangers (with H+ and Na+, mostly expressed in
nonexcitable and excitable cells, respectively), that utilize the
electrochemical gradient of the monovalent cations to prevent the
attainment of electrical equilibrium (that would imply, for a
mitochondrial membrane potential, Δψm, of−180 mV and a cytosolic
Ca2+ concentration of 0.1 μM, accumulation of Ca2+ into thematrix up
to 0.1 M).
Numerous works has given the biochemical properties of these
two pathways, and it is possible to summarize as it follows:
i) Given the huge driving force for accumulation, studies in isolated
organelles with clamped ΔΨ (by establishing K+ diffusion
potentials with valinomycin in non-respiring mitochondria)
allowed to estimate a VmaxN1400 nmol Ca2+ (mg protein)−1
min−1 and an apparent Kmb10 μM in sucrose-based media [29].
Also in isolated mitochondria, a number of inhibitors were
identiﬁed. Ruthenium compounds (typically Ruthenium Red,
RR), represent a class of non-competitive inhibitors, but unfortu-
nately their poor permeability across cellular membranes has
made it of little use in studies in intact cells. A second class of
inhibitors is divalent cations that are themselves transported by
the uniporter (e.g. Sr2+, Mn2+, Ba2+ and lanthanides).
ii) As to the efﬂux pathways, studies in isolated organelles allowed
to estimate their properties. The mitochondrial Na+/Ca2+
exchanger (mNCX) has a Vmax ranging between 2.6 (liver) and
18 nmol Ca2+ (mg protein)−1 min−1 (heart). The dependence on
Na+ is sigmoidal, with typical Km values of about 8–10 mM Na+.
Ca2+ efﬂux is inhibited by Sr2+, Ba2+, Mg2+ or Mn2+, and by a
variety of compounds of pharmacological interest such as
diltiazem, verapamil and other blockers of the voltage-dependent
calcium channels, and more speciﬁcally by CGP37157 [30]. As to
the H+/Ca2+ exchanger (mHCX), (1) it saturates at Ca2+ loads of
25 nmol (mg protein)−1; (2) its Vmax is not inﬂuenced by the
concentration of inorganic phosphate and does not exceed a rate of1.2 nmol Ca2+ (mg protein)−1 min−1; and (3) it extrudes Ca2+
against a gradient that is much higher than thermodynamically
permissible for an electroneutral H+/Ca2+ exchanger [31]. Thus,
either Ca2+ efﬂux occurs via a nH+/Ca2+ exchanger with nN2, or
it has an active component. Accordingly, Ca2+ efﬂux is inhibited
rather than stimulated by small depolarizations [32].
2.1. The permeability transition pore
This high-conductance channel (PTP) mediating mitochondrial
swelling, postulated on the basis of experimental evidence dating
back more than 40 years [33], has attracted enormous interest in the
last decade, when its role in mitochondrial dysfunction and
mitochondria-dependent cell routes has become clear. It is a high-
conductance, non-selective channel that exhibits a prominent
dependence on matrix Ca2+ and is inhibited by Cyclosporin A (CsA).
Reversible PTP openings have been resolved both in individual
isolated mitochondria [34] and in intact cells [35]. PTP could play a
role in various conditions. Long-lasting openings, triggered by
apoptotic challenges and potentiated by Ca2+-mediated cellular
signals [36] cause morphological transitions of mitochondria under-
lying the release of caspase cofactors into the cytosol, and the
initiation of the cell death process. Conversely, given the large size and
lack of selectivity of the PTP (providing charge compensation within
the channel and allowing maximal Ca2+ ﬂux at zero potential) brief
PTP openings could allow at least in principle rapid Ca2+ release from
the organelle [37].
3. Calcium routes to neurodegeneration
It was hypothesized already in the 70s that prolonged stimulation
of N-methyl-D-aspartate (NMDA) ionotropic glutamate receptors can
induce massive cell death in the brain (excitotoxicity), by causing
Ca2+ and Na+ overload in post-synaptic neurons [38]. Excitotoxicity
plays a central role in promoting cell death during neuronal ischemia
and substantial work has been placed in clarifying the different
phases of the process, and their reversibility, and the potential
pharmacological targets. It is now accepted that a primary Ca2+
increase occurs, as a consequence of direct entry through NMDA
receptors, but also following depolarization, and hence opening of
voltage-gated Ca2+ channels, release from internal stores and
reversal of the plasma membrane Na+/Ca2+ exchanger (NCX). Cell
death, however, does not depend on this initial Ca2+ rise, but rather
invariably follows a delayed massive accumulation of Ca2+, occurring
a few hours after the toxic challenge and representing a no-return
transition into the death process. Recent work has highlighted
events occurring in the interphase between the two Ca2+ rises, and
suggested a progression route into the secondary Ca2+ overload and
delayed cell death. Speciﬁcally, Bano et al. [39] showed that calpain-
mediated cleavage on NCX is a critical step for allowing the delayed
Ca2+ deregulation: inhibition of NCX cleavage protects from exci-
totoxic challenges, and conversely downregulation of the exchanger
sensitizes to sub-lethal stimuli. As to mitochondria, direct measure-
ment of matrix Ca2+ showed that the impairment of their Ca2+
uptake capacity is downstream of the delayed Ca2+ dysregulation,
and not the cause of it. Thus, the delayed Ca2+ increase is not due to
the sudden discharge from the mitochondrial buffer that still retains
the capacity to accumulate Ca2+. Rather, the delayed, massive inﬂux
of Ca2+ into the cell leads to organelle Ca2+ overload, collapse of the
electrochemical proton gradient and bioenergetic catastrophe, lead-
ing to necrotic cell death [40].
Interestingly, such a commitment mechanism appears to closely
match an emerging paradigm clariﬁed in a number of apoptotic
routes. Indeed, we and other showed that mitochondrial involvement
in apoptosis (morphological transitions and release of caspase
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with this notion, Bcl-2 reduces the state of ﬁlling of intracellular Ca2+
stores, thereby reducing mitochondrial loading upon physiological
and pathological challenges and protecting cells from apoptotic death
[25]. The pro-apoptotic protein Bax antagonizes this signalling effect,
by augmenting the state of ﬁlling of intracellular Ca2+ stores [41]. In
addition, closely mimicking the data described above in excitotoxicity,
early cleavage of plasma membrane Ca2+ pumps (PMCA) by caspases
was shown to greatly enhance the efﬁcacy of apoptotic challenges in
neurons [39] and hepatocytes [42]. In this context, one can envision a
common route to neurodegeneration in neurons, in which Ca2+ plays
an important regulatory role and eventually, by affecting the
mitochondrial checkpoint, renders cell death obligatory. Thus, while
the fate into a rapid necrotic outcome or a more controlled apoptotic
elimination will depend on the intensity of the insult and on the
bioenergetic balance of the cell, the observation of common signalling
themes and molecular targets highlights the extensive crosstalk
between the different death pathways and the potential strategies for
pharmacological intervention.
4. Looking into complex models: the pathogenesis of
neurodegenerative disorders
4.1. Alzheimer's disease (AD)
Alzheimer's disease (AD) is a devastating neurological disorder
clinically characterized by impairment of cognitive function and
changes in behavior and personality. Morphological hallmarks of the
pathology are cortical and hippocampal atrophy, accumulation of
abnormal ﬁbers in neuronal cell bodies (neuroﬁbrillary tangles
composed of a hyperphosphorylated form of the microtubular protein
tau), and the presence, in the extracellular space, of senile plaques, theFig. 2. Presenilins (PSs), Amyloid Precursor Protein (APP) and peptide β−amyloid (Aβ) can af
the expression/sensitivity of ER Ca2+ release channels (RyR and IP3R) leading to an exaggera
but not the FAD mutants, were reported to form Ca2+ permeable leak channels in the ER pro
APP can interact with the mitochondrial TIM/TOM protein import complex. The presen
mitochondrial translocation that, in turn, inhibited the entry of nuclear-encoded mitoch
enzymatic activities of cytochrome c oxidase (Cyt c-OX) and inhibition of mitochondrial A
Intra-mitochondrial Aβwas demonstrated to directly interact with cyclophilin D (CypD), the
ADmitochondriamore sensitive to PTP opening. The origin of intra-mitochondrial Aβ peptide
IMS, intermembrane space; IMM, inner mitochondrial membrane.major component of which is the peptide β-amyloid (Aβ) in two most
frequent forms, Aβ40 and Aβ42. These derive from the transmem-
brane protein APP (Amyloid Precursor Protein), that can be alter-
natively processed by three different enzymes, named α, β, and γ
secretases. The combined action of β and γ secretases leads to the
formation of a soluble fragment (sAPPβ) and of Aβ, together with its
cytosolic counterpart AICD (APP Intra-Cellular Domain) [43].
Although the majority of AD cases are sporadic, a signiﬁcant
fraction of AD is inherited in a dominant pattern. Mutations in the
genes encoding for APP and for Presenilin-1 and -2 (PS1 and PS2), two
proteins belonging to the γ-secretase enzymatic complex, have been
linked to the familial form of AD (FAD; see [44] for a recent review).
Since the majority of FAD mutations have been found to increase the
Aβ42/Aβ40 ratio, the initial hypothesis was that the disease was
dependent on the enhanced ﬁbrillization of the more amyloidogenic
Aβ42 [45].
Although this concept has never been questioned, about a decade
ago various experimental observations suggested that an alteration in
intracellular Ca2+ homeostasis could also contribute to the develop-
ment of FAD, and more in general to the pathogenesis of AD. Indeed,
PSsmutationswere shown to alter the expression, or the sensitivity, of
ER Ca2+ release channels (RyR and IP3R) in different cell models
[46–49] and in neurons from Tg AD mice [50,51], leading to the “Ca2+
overload” hypothesis [45,52], i.e. the idea that exaggerated ER Ca2+
release affects cellular targets such as mitochondria, favouring cellular
demise (Fig. 2). The Ca2+ overload mechanism has however remained
largely mysterious until it was found that wt PSs, but not the FAD
mutants, can form Ca2+ permeable leak channels in the ER [53,54],
thus providing a clear case for enhanced Ca2+ release in the
pathological model. Although the data are straightforward, and
support a very appealing model, the following work in other
laboratories was not entirely consistent with the ﬁrst formulation offect mitochondrial functionality by differentmeans. FAD-linked PSsmutationsmay alter
ted ER Ca2+ release that in turn may cause abnormal mitochondrial Ca2+ uptake. wt PSs,
viding a clear explanation for the enhanced Ca2+ release found in different AD models.
ce of an acidic domain within APP sequence may be responsible for an incomplete
ondrial proteins. Mitochondrial Aβ accumulation has been correlated with impaired
β-binding alcohol dehydrogenase (ABAD), leading to mitochondrial oxidative damage.
PTP component that binds CsA and renders the channel more sensitive to Ca2+, making
s is however unclear. ER, endoplasmic reticulum; OMM outermitochondrial membrane.
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[60–62] showed that some FAD-linked PS2 mutations caused a
reduction, not an increase, in ER/Golgi Ca2+ levels. This experimental
discrepancy, while not disproving the Ca2+ hypothesis, may thus allow
two possible conclusions. The ﬁrst is that the system is likely to be very
complex, with additional unidentiﬁed regulatory elements, and the use
of different cell systems and experimental approaches (e.g. silencing or
overexpression, knock-out or knock-in models) may trigger equally
different compensatory mechanisms and calcium effects in the cells.
Secondly, given that the discrepanciesmostly refer to PS2, a speculative,
but appealing, possibility is that PS2 and PS1 play distinct roles in ER/
Golgi Ca2+ handling. In particular, FAD-PS1 mutations, that cause an
increase in the ER Ca2+, unavoidably exacerbate cell death. Conversely,
PS2 mutants, by favouring low ER Ca2+ levels, might confer relative
protection to other routes of cell intoxication, such as Aβ peptides and
oxidative damage. This hypothesis would be consistent with the above
described role of the ER/mitochondrial Ca2+ relationship, and with the
clinical observation that FAD-linkedPS2mutationshavebeenassociated
to milder phenotypes [60–62].
No matter how the synergistic “Ca2+ hit” occurs, mitochondrial
dysfunction appears an obligatory downstream step in the pathogen-
esis of AD. Decreased cytochrome c oxidase activity, increased free-
radical generation leading to oxidative stress and reduced energy
metabolism was described in the brain of AD patients before Aβ
plaques formation [63–67]. Moreover, electron microscopy analysis of
mitochondria in various regions of AD brain revealed signiﬁcant
morphological organelle alterations, such as reduced size of mito-
chondrial cristae [68].
As to the mechanism, converging evidence points to a role for Aβ
peptides and the PTP and, possibly, to a Ca2+-sensitization step.
Endogenous as well as ectopically expressed wt or FAD-linked
Swedish APP have been found to localize to mitochondria in different
cell types [69–71]. In isolated mitochondria, Aβ peptides were
shown to inhibit mitochondrial respiration [72,73] and, in the
presence of Ca2+, cause the opening of PTP. The involvement of PTP
was further reinforced by the analysis of mouse models in which
cyclophilin D, (CypD), the PTP component that binds CsA and renders
the channel more sensitive to Ca2+, was knocked out [74,75].
Interestingly, this genetic alteration substantially improves the
cognitive abilities of a mouse model of AD and alleviates Aβ-mediated
reduction of long-term potentiation [76]. Moreover, intra-mitochon-
drial Aβ was demonstrated to directly interact with CypD, thus
providing amolecular basis for this pathogenic mechanism [76]. Other
putative damaging effects of Aβ were reported. In PC12 cells, Aβ
blocked the entry of nuclear-encoded proteins into mitochondria
causing decreased mitochondrial membrane potential, increased ROS
production, oxygen glucose deprivation and altered mitochondrial
morphology [77]. In another study, Aβ increased neuronal ROS
production, activated mitochondrial ﬁssion proteins Drp1 and Fis1
and caused mitochondrial fragmentation [78]. Finally, in the mito-
chondrial matrix Aβ peptides were shown to interact with and inhibit
the activity of mitochondrial Aβ-binding alcohol dehydrogenase
(ABAD), leading to mitochondrial oxidative damage, increased
carbonylation of mitochondrial proteins and impaired activity of
respiratory complexes. Some of these alterations were found to occur
in AD mouse models before the development of senile plaques,
suggesting that mitochondrial dysfunction is an early event in the
pathogenesis of the disease [79].
Thus calcium andmitochondriamay represent the common theme
linking the various reported aspects of the pathogenesis of AD. Several
aspects remain however to be solved, and we wish to point out two
crucial ones. The ﬁrst is a clear understanding of the dysregulation of
calcium signalling, as discussed above. The second one refers to the
origin of intra-mitochondrial Aβ, if a primary role is attributed to this
molecule. Experiments of limited trypsin proteolysis and chemical
cross-linking showed that APP interacts with the mitochondrial TIM/TOM protein import complex and its orientation is such that the N-
terminal resides inside the mitochondria while the large C-terminal
part of the protein faces the cytosol [69,71]. Thus, although the
presence within mitochondria of γ-secretase constituents and func-
tional γ-secretase activity has been reported [80], it is unlikely that Aβ
is being produced on the matrix side. Moreover, the mitochondrial
presence of functional β-secretase, essential for the generation of the
C99 peptide, substrate for γ-secretase, has not been reported yet. As to
direct permeation from the ER, the Golgi complex or secretory vesicles
to the cytosol, and then across the outer and the inner mitochondrial
membranes (the latter notoriously highly impermeable to most
solutes, including ions), this audacious possibility awaits experimen-
tal conﬁrmation.
4.2. Huntington's disease (HD)
Huntington's disease (HD) is a progressive neurodegenerative
disorder characterized by motor, cognitive and psychiatric symptoms
including depression, personality changes, weight loss, dementia and
motor disturbances. The latter are characterized by uncontrolled
movements (chorea), developing in the terminal stage into severe
akinesia. The disease is inherited in an autosomal dominant fashion
and the mutation responsible for the disease was identiﬁed as a CAG-
triplet expansion in exon 1 of huntingtin gene. The CAG sequence
codes for glutamine and in HD, an expansion of the polyglutamine
(polyQ) stretch beyond 35 glutamines results in pathogenicity and
causes the selective death of the GABAergic spiny neurons of the
striatum. The length of the polyQ stretch inversely correlates with the
age of onset symptoms. Mutant Huntingtin (polyQ-Htt) forms
intracellular aggregated, particularly in cell nuclei, and, to a lesser
extent, in the cytoplasm, neurites, and terminals [81]. The aggregates
have both been suggested to be toxic as well as neuroprotective to the
cells. The exact function of Htt is still unknown: it is considered a
scaffolding proteinmediating protein–protein interactions and to play
a role in processes as diverse as axonal transport, regulation of
transcription, exocytosis, Ca2+ homeostasis, bioenergetic metabolism
and prevention of apoptosis [82]. Dysfunctions in any one of these
processes could be involved in the etiology of HD.Moreover, a series of
seminal, independent observations have highlighted a possible role
for Ca2+ and mitochondria also in this neurodegenerative disorder
(Fig. 3). The ﬁrst experimental evidence linking neurodegeneration in
HD to mitochondrial impairment was the observation that treatment
of mice with 3-nitropropionic acid (3-NPA), an inhibitor of complex II
of the respiratory chain, induces a degeneration of striatal neurons in
vivo, recapitulating HD pathogenesis [83]. In addition, the activities of
the respiratory complexes II, III and IV were shown to be reduced in
HD [84]. Then, Panov et al. showed that mutant but not wild type Htt
directly impairs mitochondrial function. They also proposed that
mutant Htt localize on mitochondrial membranes in the neurons of
mutant mice, suggesting that a direct relationship may occur between
the observed defects and the disease [85]. Finally, Bezprozvanny et al.
demonstrated that Htt forms a ternary complex with Htt-associated
protein-1A (HAP-1A) and type 1 IP3Rs. In this complex, polyQ-Htt, but
not the wild type Htt, facilitates Ca2+ release from the ER and renders
neuronsmore sensitive to Ca2+-mediated cellular dysfunction [86]. As
to the mechanistic link, mitochondrial Ca2+ overload appeared the
decisive commitment step [87]. In keeping with this view, Choo et al.
showed that mutated, but not wild type, Htt induces PTP opening in
isolated mitochondria [88], and we recently demonstrated a facili-
tated opening of PTP in permeabilized polyQ-Htt expressing cells [89].
Thus, also in this case PTP appears to be the ﬁnal commitment step in a
number of cellular stress conditions, with Ca2+ acting as a potent
sensitizing factor [89]. As to the stress signals converging on
mitochondria, logical candidates are ROS, putatively involved in age-
related disorders and in conditions of mitochondrial impairment.
Interestingly, the coordinated genomic program mediated by
Fig. 3. Mutant Huntingtin (mutHtt) impairs mitochondrial function by transcriprional and non-trascriptional mechanisms. The transcriptional effects are mediated by nuclear
translocation of mutHtt. One important consequence of the regulation of gene transcription is the downregulation of PGC1α, and thus the reduced expression of nuclear-encoded
mitochondrial proteins involved in the respiratory chains and in the oxidative-stress defense. MutHtt also associates with the outer mitochondrial membrane (OMM) directly
affecting the PTP opening susceptibility andmaking striatal neurons more vulnerable to excitotoxic stimuli. MutHtt reduces complex II activity and the treatment with the complex II
inhibitor 3-nitropropionic acid (3-NPA) induces striatal neurodegeneration in vitro and in vivo. The association of mutHtt with HAP-1A and with the IP3R type I facilitates ER Ca2+
release, thus making mitochondria more susceptible to Ca2+ overload. ER, endoplasmic reticulum; IMS, intermembrane space; IMM, inner mitochondrial membrane.
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transcription factor that upregulates ROS-scavenging systems upon
oxidative stress [90], appears dysfunctional in HD striata [91], and also
in cellular models of the disease [92]. Indeed, in both cases the level of
the PGC-1α transcript is downregulated, and, at least in part, the
scavenging enzymes are accordingly reduced. This observation
appears very appealing, as recent work has highlighted PGC-1α
transcriptional regulation as a promising drug target [93].
Another important way in which mitochondrial function could be
impaired inHD is through abnormal axonal trafﬁcking ofmitochondria
to and from the synapse. PolyQ-Htt has beenproposed to inhibit axonal
transport through severalmechanisms and, recently, itwas shown that
fragments of Htt associate with mitochondria thus interfering with
their microtubule-associated transport [94]. Overall, the data so far
obtained appear very coherent, and highlight a straightforward
pathogenic route, based on the triggering of a calcium-dependent
mitochondrial dysfunction. What remains to be assessed is how the
putative damaging effects of polyQ-Htt are coordinately regulated. Are
mitochondrial respiratory deﬁciencies and calcium-mediated orga-
nelle dysfunction two independent effects of mutated Htt, or are they
causally linked? Or does the latter gradually induce the former, in a
vicious cycle of ROS production and genetic damage that can be further
exacerbated by toxic challenges affecting the brain?And in this picture,
why isn't PGC-1α and its anti-oxidant program upregulated? Relative
to the respiratory deﬁciencies, recent work on cultured striatal
neurons transfected with a polyQ-Htt showed downregulation of
complex II components at the protein, but not at the mRNA, level [95].
Complex II deﬁciency appears thus due to a post-transcriptional
(proteolytic) effect. Whether a calcium-sensitive protease (e.g.
calpains) is involved, as was reported in other non genetic models of
neurodegeneration [39], has yet to be demonstrated.
4.3. Parkinson's disease (PD)
Parkinson's disease (PD) is a chronic progressive neurodegenera-
tive disorder clinically characterized by motor impairments involvingresting tremor, progressive rigidity, bradykinesia and postural
instability. PD pathology is characterized most prominently by loss
of dopaminergic neurons in the substantia nigra and formation of
intraneuronal protein aggregates called Lewy body.
Mitochondrial involvement in PD has been an established notion
for many years, since the recognition of the mechanism of action of
MPTP (1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine). This com-
pound is formed during production of synthetic heroine, and its
metabolite MPP+ is a mitochondrial toxin, that blocks complex I of
the respiratory chain. In drug abusers, it causes a form of PD that is
clinically indistinguishable from the sporadic variety. Further studies
corroborated this observation. Biochemical analysis of PD samples
revealed the presence of a mild, systemic defect of complex I, and
chronic exposure to the most classical complex I inhibitor (rotenone)
accurately recapitulated the pathological, biochemical, and behavioral
features of PD. The mechanism of complex I inhibition toxicity
probably involves oxidative stress, caused by the block of the
respiratory chain, but the selective vulnerability of dopaminergic
neurons still remain elusive to explain [96].
The recent identiﬁcation of a cohort of genes involved in the
familial forms of PD further corroborates the notion of mitochondrial
involvement, as apparently unrelated proteins seem to share this
organelle as a common theme, and possibly point to a signalling role
for Ca2+ (Fig. 4). Speciﬁcally, mutations were reported in genes
encoding for α-synuclein, DJ-1, Leucin Rich-Repeated Kinase (LRRK2),
ubiquitin C-terminal hydrolase L1 (UCHL1), phosphatase-tensin
homologue (PTEN)-induced kinase 1 (PINK1), and parkin, as well as
within the mtDNA (for a recent review, see [97]). Mutations in the
gene encoding the mitochondrial serine protease HtrA2 have also
been linked to PD in several families.
α-synuclein mutations are linked to autosomal dominant familiar
PD. Inclusions immunopositive for α-synuclein are found in Levy's
body, raising to the possibility that the toxicity of the protein is due to
an abnormal form of aggregation or ﬁbril formation, in analogy on
what happens in AD. In a recent study [98] the different levels of α-
synuclein oligomerization have been linked to cell death. In particular,
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to Ca2+ dysregulation, probably via a pore-forming mechanism.
Calpain, a major Ca2+-activated protease, can cleave α-synuclein,
producing a truncated form more prone to aggregate, thus leading to
formation of protoﬁbrils [99]. Overall, these observations suggest that
a vicious cycle of Ca2+ dysregulation (coordinately activated by the
oligomers and, possibly, excitotoxic stimulation) and ﬁbril deposition
eventually leads to severe Ca2+ overload, to the point of mitochondrial
permeability transition and commitment to neuronal cell death.
Parkin has been identiﬁed as a ubiquitin-protein ligase (E3) that
acts along with the ubiquitin-conjugating enzymes (E2s) in selectivity
of ubiquitination and recognition of substrates [100]. Inactivation of
parkin leads to reduction in UPS-mediated degradation of its
substrates, among which a glycosylated form of α-synuclein. Inter-
estingly, Drosophila parkin null mutants exhibited defects in mito-
chondrial function with signs of increased oxidative stress, muscle
degeneration and male sterility. Reduced levels of mitochondrial
proteins involved in mitochondrial oxidative phosphorylation were
also reported in parkin-knock-out mice, which exhibited normal brain
morphology, but increased striatal extracellular dopamine levels
[101]. Overexpression of parkin in cultured cells prevents mitochon-
drial swelling and stress-induced apoptosis. The protein appears
localized in the mitochondrial matrix, where it enhances mitochon-
drial gene transcription and biogenesis in proliferating cells, but the
exact mechanism for the protective function of parkin inmitochondria
is unknown [102]. Recently, parkin has been shown to promote the
selective clearance of damaged mitochondria through the mitophagic
process [103] further reinforcing the concept that it has a neuropro-
tective role.
PINK1 is highly conserved protein, containing a catalytic serine-
threonine kinase domain, ubiquitously expressed in the human brain.
It is unambiguously localized to mitochondrial membranes, and its
overexpression protects cells from mitochondrial depolarization and
apoptosis induced by the proteosomal inhibitor MG132, and from
mitochondrially-induced apoptosis triggered by staurosporine [104].Fig. 4. Mutations in familial PD-linked genes encoding α-synuclein (α-syn), parkin, pin
pathways. Mutant α-syn promotes Ca2+ inﬂux and mitochondrial Ca2+ overload and muta
protein targets: genetic data suggest that pink1 is upstream of parkin, and that all of them e
mitochondrial-induced apoptosis. LRRK2 mutations induce apoptotic death through cytoch
inhibition by MPTP or rotenone causes dopaminergic degeneration. Mutations in mtDN
mitochondrial membrane; IMS, intermembrane space; IMM, inner mitochondrial membranLoss of function mutations are responsible for male sterility, and
muscle and dopaminergic neuronal degeneration in Drosophila [105].
Overexpression of parkin was shown to rescue the mitochondria
dysfunction caused by PINK1 deﬁciency (but did not rescue the
increased sensitivity of PINK1 mutant ﬂies to apoptosis), suggesting
that the two proteins could cooperate (probably regulating the
balance between mitochondrial ﬁssion and fusion, [106]) in preser-
ving mitochondrial integrity in various stress conditions [107].
Interestingly, mutant PINK1 has been shown to exacerbate mitochon-
drial alterations (disturbing the mitochondrial Ca2+ ﬂuxes) promoted
by mutant α-synuclein, thus suggesting a cooperative role of these
two proteins [108].
LRRK2 is a recently found gene, mutated in familiar late-onset PD.
Its product is a kinase [109] and a signiﬁcant fraction of the protein is
associated with mitochondria [110]. Pathogenic PD mutations are
linked to activation of the intrinsic apoptotic pathway, with
cytochrome c released into the cytosol and activation of caspase-3
[111].
Finally, little is known of the function of the DJ-1 gene product. DJ-
1 expression is particularly abundant in brain regionwhere it is largely
cytoplasmic except for a pool localized in mitochondria. In particular,
DJ-1 was reported to be located in the mitochondrial intermembrane
space and in the matrix, while very little, if any, is associated with
outer or inner mitochondrial membranes. This ﬁnding suggests that
DJ-1 may act within mitochondria but its precise neuroprotective
mechanism remains obscure (for a review, see [112]). Recent ﬁndings
suggest that DJ-1 is an atypical peroxiredoxin-like peroxidase [113]
indicating that it may play a role in reducing mitochondrial oxidative
stress.
These data highlight mitochondria involvement in PD. Obviously,
an intriguing possibility is that mitochondrial Ca2+ homeostasis, and
thus the sensitivity to Ca2+-mediated challenges, are directly or
indirectly controlled by these proteins. Work on this topic is under
way in several laboratories, including ours, and it is easy to predict
that also in this model of neurodegeneration the concerted action ofk1, DJ-1 and LRRK2 cause mitochondrial dysfunctions through common intersecting
nt parkin exacerbates this effect. DJ-1, PINK1 and Parkin may act in series on the same
xert a protective role preserving mitochondrial functions, morphology and preventing
rome c release and activation of caspase-3. Complex I activity is reduced in PD and its
A-encoded complex I subunits also cause PD. PM, plasma membrane; OMM outer
e.
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the mechanism leading through time to neuronal dysfunction.
Indeed, preliminary evidence from our laboratory, demonstrating
an alteration in mitochondrial Ca2+ homeostasis in a PD model,
supports this possibility. Speciﬁcally, by using recombinant aequorin
to evaluate Ca2+ ﬂuxes [3] we observed an alteration of mitochon-
drial Ca2+ signals in SH-SY5Y cells overexpressing wild type or
mutated (G2019S and R1441C) LRRK2, associated with PD (Celsi in
preparation).
Overall, the picture emerging from the study of the pathogenesis of
the neurodegenerative disorders appears terribly complex, with many
uncertainties and gaps to ﬁll. Nevertheless, the common role of
mitochondria dysfunction (metabolic, morphologic or dynamic)
appears very clear, and provides not only a leading theme for further
studies, but also a promising pharmacological target in these
devastating diseases.
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